Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

 
• By Neena Brizmohun

EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.

Alzheimer's patient
Donanemab was shown to significantly slow cognitive and functional decline in people with early symptomatic Alzheimer's disease • Source: Shutterstock

More from Europe

More from Geography